Search

everythinglearnresearchcommunity

for

Search:↓

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

Targeted immune modulation can help achieve stable remission in alopecia areata.

Targeting NETs may help reduce fibrosis in Crohn's disease.

Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.

A new treatment using gold nanoclusters can safely reduce unwanted hair growth.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.

New cytokine-targeted therapies show promise for treating alopecia areata.

CTP-543 is generally safe for treating alopecia areata.

Targeting Vδ1+T-cells may help treat alopecia areata.

A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.

Trastuzumab may cause tufted hair folliculitis as a side effect.

Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.

JAK inhibitors are effective treatments for alopecia areata.

IL-17 plays a key role in severe hair loss in chronic alopecia areata.

The new ddPCR method reliably detects unwanted viruses in CAR-T cell products, ensuring their safety for patients.

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.

Blocking YAP/TAZ could be a new way to treat skin cancer.

TAZ boosts fat cell formation in goat stem cells by activating a specific signaling pathway.

Recombinant thymosin β4 promotes blood vessel growth and reduces muscle damage.

CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.

Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.

Misdiagnosis led to unnecessary treatment due to a genetic mutation affecting thyroid hormone resistance.